Tin tức & Cập nhật
Xem bài viết Sản phụ khoa
Xem
Chỉ hiển thị Multimedia

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC
20 Jan 2023
bởiRoshini Claire Anthony
Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.
20 Jan 2023

Signs of heavy menstrual bleeding often missed; standardized criteria for assessment needed
20 Jan 2023
bởiJairia Dela Cruz
Healthcare professionals (HCPs) and women themselves may overlook the signs of heavy menstrual bleeding, with most HCPs failing to recognize the key indicators for bleeding disorders and perform assessments for patients with heavy menstrual bleeding, according to a study presented at ASH 2022.
20 Jan 2023






